Astellas Pharma (ALPMY)
(Delayed Data from OTC)
$9.47 USD
-0.02 (-0.21%)
Updated Apr 24, 2024 03:59 PM ET
4-Sell of 5 4
B Value F Growth F Momentum D VGM
Income Statements
Fiscal Year end for Astellas Pharma Inc falls in the month of March .
All items in Millions except EPS data.
3/31/24 | 3/31/23 | 3/31/22 | 3/31/21 | 3/31/20 | |
---|---|---|---|---|---|
Sales | NA | 11,418 | 10,624 | 11,257 | 11,934 |
Cost Of Goods | NA | 2,168 | 2,074 | 2,217 | 2,539 |
Gross Profit | NA | 9,250 | 8,550 | 9,040 | 9,395 |
Selling & Adminstrative & Depr. & Amort Expenses | 0 | 8,250 | 7,274 | 7,814 | 7,156 |
Income After Depreciation & Amortization | 0 | 1,000 | 1,276 | 1,226 | 2,239 |
Non-Operating Income | NA | 61 | 50 | 105 | 40 |
Interest Expense | NA | 66 | 41 | 21 | 28 |
Pretax Income | NA | 995 | 1,286 | 1,309 | 2,251 |
Income Taxes | NA | 253 | 269 | 223 | 458 |
Minority Interest | NA | 0 | 0 | 0 | 0 |
Investment Gains/Losses | NA | 0 | 0 | 0 | 0 |
Other Income/Charges | NA | 0 | 0 | 0 | 0 |
Income From Cont. Operations | NA | 742 | 1,017 | 1,086 | 1,793 |
Extras & Discontinued Operations | NA | 0 | 0 | 0 | 0 |
Net Income (GAAP) | NA | 742 | 1,017 | 1,086 | 1,793 |
Depreciation Footnote | 3/31/24 | 3/31/23 | 3/31/22 | 3/31/21 | 3/31/20 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | 0 | 1,795 | 1,929 | 1,881 | 2,848 |
Depreciation & Amortization (Cash Flow) | NA | 795 | 653 | 655 | 609 |
Income After Depreciation & Amortization | 0 | 1,000 | 1,276 | 1,226 | 2,239 |
Earnings Per Share Data | 3/31/24 | 3/31/23 | 3/31/22 | 3/31/21 | 3/31/20 |
---|---|---|---|---|---|
Average Shares | NA | 1,825.06 | 1,850.60 | 1,857.22 | 1,877.51 |
Diluted EPS Before Non-Recurring Items | NA | 0.91 | 0.60 | 0.61 | 0.96 |
Diluted Net EPS (GAAP) | NA | 0.41 | 0.55 | 0.58 | 0.95 |
Fiscal Year end for Astellas Pharma Inc falls in the month of March .
All items in Millions except EPS data.
3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 | |
---|---|---|---|---|---|
Sales | NA | 2,857.32 | 2,714.06 | 2,737.43 | 2,678.87 |
Cost Of Goods | NA | NA | NA | 503.31 | NA |
Gross Profit | NA | NA | NA | 2,234.11 | NA |
SG&A, R&D, and Dept/Amort Expenses | 0.00 | 0.00 | 0.00 | 1,899.81 | 0.00 |
Income After SG&A, R&D, and Dept/Amort Expenses | 0.00 | 0.00 | 0.00 | 334.30 | 0.00 |
Non-Operating Income | NA | NA | NA | 27.56 | NA |
Interest Expense | NA | NA | NA | 19.86 | NA |
Pretax Income | NA | NA | NA | 342.01 | NA |
Income Taxes | NA | NA | NA | 100.16 | NA |
Minority Interest | NA | NA | NA | 0.00 | NA |
Investment Gains/Losses | NA | NA | NA | 0.00 | NA |
Other Income/Charges | NA | NA | NA | 0.00 | NA |
Income From Cont. Operations | NA | 126.32 | -10.10 | 241.84 | -348.80 |
Extras & Discontinued Operations | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | NA | 126.32 | -10.10 | 241.84 | -348.80 |
Earnings Per Share Data | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 |
---|---|---|---|---|---|
Average Shares | NA | 1,800.48 | 1,823.75 | 1,794.64 | 1,825.06 |
Diluted EPS Before Non-Recurring Items | NA | 0.12 | -0.01 | 0.13 | 0.15 |
Diluted Net EPS (GAAP) | NA | 0.07 | -0.01 | 0.13 | -0.19 |